

Effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors in adults with central obesity: study protocol for a randomized controlled study

Juan Zhou

Shenzhen Nanshan Centre for Chronic Disease Control

Dan Zhao

Shenzhen Nanshan Centre for Chronic Disease Control

Ning Wang

Huazhong University of Science and Technology Tongji Medical College

Zhiwei Zeng

Shenzhen Nanshan Centre for Chronic Disease Control

Changyi Wang

Shenzhen Nanshan Centre for Chronic Disease Control

Liping Hao

Huazhong University of Science and Technology Tongji Medical College

Xiaolin Peng (✉ xiaolinpeng@hotmail.com)

Shenzhen Nanshan Centre for Chronic Disease Control

Study protocol

Keywords: Lutein supplementation, central obesity, inflammatory biomarkers, metabolic risk factors

Posted Date: December 19th, 2019

DOI: <https://doi.org/10.21203/rs.2.13018/v3>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on January 6th, 2020. See the published version at <https://doi.org/10.1186/s13063-019-3998-8>.

Abstract

Background: The prevalence of central obesity is increasing consistently, and visceral fat is associated with increased production of inflammatory factors and metabolic risk factors. Lutein might retard the development of metabolic disease through its antioxidant and anti-inflammatory properties. Furthermore, epidemiological studies have associated higher dietary intake and serum levels of lutein with decreased adiposity. However, few randomized controlled trials (RCTs) have shown the effects of lutein supplementation on inflammatory biomarkers and metabolic risk factors, especially in adults with central obesity.

Methods: This study will be conducted as a double-blinded, parallel placebo-controlled clinical trial in which 120 people with central obesity aged 18-60 years old and willing to provide informed consent will be randomly assigned to the intervention or placebo group in a 1:1 ratio according to sex, age and waist circumference. The intervention group will receive 10 mg daily lutein supplementation for 12 weeks to explore the effect of lutein supplementation on serum lutein, glycaemic and lipid profiles, inflammatory factors and body composition. Two populations (intention-to-treat population and per-protocol population) will be used in the data analyses.

Discussion: Our findings from this trial will contribute to the knowledge of the association between lutein supplementation and inflammatory biomarkers and metabolic risk factors in people with central obesity, which will offer a possibility for the prevention of inflammatory diseases.

Introduction

The prevalence of obesity has constantly increased and has reached epidemic proportions. The WHO estimated that by 2016, 39% of adults aged 18 years and over were overweight and 13% were obese worldwide [1]. Obesity represents a major risk factor for an expanding set of chronic diseases, such as type 2 diabetes mellitus, hypertension, cardiovascular diseases and cancer [2–4]. Specifically, central obesity, which occurs when excessive abdominal fat is deposited around the stomach and abdomen, is considered to be the most detrimental type of obesity and is accompanied by an increased risk of mortality [5,6]. Substantial studies have suggested that oxidative stress and inflammation may be mechanistic links between obesity and metabolic diseases [7].

It is clear that the levels of oxidative stress and inflammatory factors increase as the amount of adipose tissue increases. The adipokines (interleukin-6 (IL-6), tumour necrosis factor- α (TNF- α), adiponectin, leptin and resistin) secreted by adipose tissue play a role in the homeostasis of various physiological processes, such as insulin sensitivity, energy expenditure and fatty acid oxidation [8, 9]. Compared to other fat deposits, however, visceral fat has more adverse effects, including higher levels of free fatty acids, inflammatory molecules, and adipocytokines [10–13]. Epidemiological studies have indicated that visceral fat is correlated with insulin resistance (IR) and glucose intolerance as well as increasing levels

of C-reactive protein (CRP), TNF- α , IL-6, isoprostanes and monocyte chemoattractant protein-1 (MCP-1) [13, 14].

Lutein is an oxygenated carotenoid that is found primarily in dark green leafy vegetables and egg yolks. Lutein is mostly known for its effects on visual function and its preventative effect against macular degeneration, potentially acting as an antioxidant that protects against light-induced oxidative damage in the retina by oxygen radicals [15, 16]. Given the beneficial antioxidant and anti-inflammatory properties [16], it is hypothesized that lutein may have beneficial effects on inflammatory biomarkers and metabolic risk factors. Xu et al. [17] provided early atherosclerosis patients with lutein supplementation and found that the intervention group had a significant decrease in serum IL-6 and MCP-1. Another intervention study conducted in healthy nonsmokers revealed that lutein supplementation increased total antioxidant capacity and reduced CRP [18]. Although accumulating epidemiological studies have shown an inverse relationship between serum carotenoid concentrations and circulating markers of inflammation, such as CRP and soluble intercellular cell adhesion molecule-1 (ICAM-1), intervention studies have focused mostly on other carotenoids, such as lycopene [19, 20], and less on lutein.

Another hypothesis is that lutein may have anti-adiposity effects. Our previous study found that lutein treatment significantly decreased body weight as well as abdominal and total adipose tissue, which were increased by high-fat-diet feeding in mice [21]. In addition, the concentrations of total cholesterol (TC) and triglycerides (TGs) in the serum and liver as well as the serum levels of low-density lipoprotein cholesterol (LDL-C) were significantly reduced [21]. In addition, epidemiological studies have associated higher dietary intakes and serum levels of lutein with decreased adiposity [22–24]. Despite animal studies and human epidemiological studies linking lutein to adiposity, however, there is a paucity of randomized controlled trials (RCTs) utilizing lutein supplementation to assess changes in adiposity.

An important aspect to consider with lutein supplementation is that it cannot be synthesized by humans and can be obtained through only diet or supplements. However, our previous study revealed that the median intake of lutein (2.499 mg/d) is far below the special proposed level (SPL: 10 mg/d) that is recommended in the 2013 Chinese Dietary Reference intakes [25]. In addition, although the antioxidant properties of lutein have been proven in different populations, reports dealing specifically with lutein in people with central obesity are scarce. In light of the information above, providing lutein supplementation to people with central obesity is worthy of exploration.

Methods

Study design and setting

This is a double-blind, parallel randomized controlled trial enrolling participants with central obesity. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 statement will be followed in this trial (Additional file 1: SPIRIT checklist) [26]. The proposed clinical trial will be conducted at the Community Health Service Centre (CHSC) in Nanshan District, Shenzhen, Guangzhou Province,

China for 12 weeks to assess the effects of lutein supplementation (10 mg/d) on inflammatory biomarkers and metabolic risk factors in adults with central obesity. Figure 1 illustrates the overview of the study.

Study participants and eligibility criteria

It is estimated that 52 participants per treatment group would be required for 80% power and a 5% level of significance to detect the change in serum TGs over 12 weeks of supplementation [27]. Allowing for a dropout rate of approximately 15%, we aim to recruit 120 participants in total. Participants were eligible for this study if they fulfilled the following criteria: (1) aged between 18 and 60 years; (2) waist circumference (WC) \geq 90 cm for males and \geq 85 cm for females; (3) deficient lutein intake (dietary lutein intake \leq 10 mg/d); and (4) willing to sign the informed consent form. People meeting any of the following criteria will be excluded from participation: (1) use of lutein supplementation or related health care products with 1 month; (2) use of antibiotics within 1 month; (3) secondary obesity; (4) adoption of a special diet or meal replacement in the previous 2 weeks; (5) use of insulin or insulin sensitizers within 1 month; (6) chronic diseases (including type 2 diabetes, hypertension and dyslipidaemia) for over 10 years; (7) hepatorenal dysfunction (creatinine $>$ 1.2 times the upper normal limit of creatinine, aspartate aminotransferase (AST) $>$ 1 time the upper normal limit); (8) any active tumours/cancers; (9) regular use of drugs affecting blood lipid; (10) pregnancy or lactation; or (11) history of gastrointestinal surgical operation.

Randomization and blinding

After the inclusion and exclusion criteria are assessed and informed consent is obtained, participants will be allocated to the lutein group or the placebo group. Computer-generated random numbers will be used for allocation sequence generation with stratification completed according to sex, age and WC. This part of the study will be performed by a person who will be operationally independent from the study team. Allocation concealment will be implemented by using a random number card in a black envelope. The details of the allocation will be concealed from the investigators, outcome assessors and the patients until all data collection is complete. Patients' collected data will be kept confidential during this trial.

Steering committee and monitoring

The steering committee consists of JZ, DZ, NW, ZW-Z, CY-W, LP-H and XL-P. The steering committee is responsible for the design, reporting and publication of the trial. Clinical trial monitoring will be performed by an independent monitor who will check and verify reports and documents. The frequency of monitoring can be adjusted according to the total enrolment period and enrolment rate.

Supplements

The participants will receive either 10 mg of lutein or placebo capsules per day for 12 weeks. Lutein (10 mg) will be mixed with pregelatinous starch (240 mg) and provided in acid-soluble gelatine capsules, and the placebo will contain pregelatinous starch (250 mg). To maintain and guarantee blinding, the capsules will be identical in appearance, shape, smell and weight. All capsules will be provided by the Angel Nutrition Co., Ltd. (Yichang, China). Face-to-face instruction on how to take the capsules will be provided at the baseline. The enrolled participants will be required to (1) take one capsule along with meals daily; (2) avoid making any changes to dietary habits, physical activity level (PAL) or medicine use; and (3) record changes in dietary habits, PAL and medicine use in a timely manner.

Study Procedures

Recruitment and screening

Table 1 provides the schedule for enrolment, intervention and follow-up. Participants will be recruited by placing advertisements on social media sites and community bulletin boards. Once a volunteer expresses initial interest in participating in the study, he/she will have face-to-face or telephone communication with the research assistant. Detailed information on the study trial, including the purpose, the methods of the intervention and duration, will be provided to the volunteers. If they are still interest in this project after careful consideration, the structured standardized screening questionnaire, which is mainly based on the inclusion and exclusion criteria for the study, will be used to assess the potential eligibility of the participants for the study. Potential participants who are found not to be eligible will be excluded at this stage. Eligible participants will be invited to attend a further screening visit, which will take place at the CHSC. First, informed consent will be obtained from all participants. Second, for safety assessments, liver and renal function will be evaluated by collecting fasting blood samples and spot urine samples. Third, the anthropometric index will be measured by the trained investigators.

Test visit

At test visit 1 (week 0), eligible participants will be allocated to either a lutein supplement group or a control group. The lutein supplement group will take one 10 mg lutein capsule daily, and the control group will take the placebo. Participants will be given a 6-week supply of capsules at both visit 1 and visit 2 and will be required to return the remaining capsules at the next visit, which will be counted and recorded for each participant to ensure compliance with the protocol. Participants will be defined as non-compliant if they took less than 80% of the study product. Medication, health status or any recent changes around the inclusion and exclusion criteria since the completion of the screening questionnaires will also be re-assessed to evaluate whether participants are still suitable to participate in the study. Anthropometric measurements, dietary assessments and blood samples will be collected at each visit, and stool samples

and spot urine samples will be collected at test visit 1 and test visit 3. At test visit 1 and test visit 3, the volunteers will be asked to complete the short form of the International Physical Activity Questionnaire (IPAQ-short form) and the Mini-mental State Examination (MMSE). At the end of each visit, participants will be thanked for their time and will be provided with breakfast. After test visit 3, people in the placebo group will be given the same amount of lutein supplements as that provided to the intervention group. The full details of the data that will be collected at each time point can be found in Table 1.

Anthropometric measurements

Anthropometric measurements will be collected using standardized equipment and examination procedures. The weight and height of the participants will be measured while they are wearing light clothes and no shoes in the morning of the follow-up. Body fat percentage and total body water will be calculated using a one-stop self-service monitoring machine (E-Techco Information Technologies Co., Shenzhen, China). WC will be measured at the midpoint between the lower edge of the rib arch and the iliac crest while the subjects are standing and breathing steadily. The hip circumference (HC) will be measured at the widest part of the buttocks at the intertrochanteric level to the nearest 0.1 cm. The other anthropometric indexes will be calculated using the following equations: body mass index (BMI) = weight (kg)/height (m²); waist-to-hip ratio (WHR) = waist (m)/hip (m); and waist-to-height ratio (WHtR) = waist (m)/height (m). Blood pressure (BP) will be measured using a standard mercury sphygmomanometer with a cuff placed on the upper right arm after a 5-min rest with 1-min intervals before subsequent measurements. Three BP readings will be recorded, and the mean will be calculated. All anthropometric measures will be taken by trained research assistants using standard equipment according to the standard guidelines.

Biological sampling

At the baseline, middle and end of the trial, 12 ml of venous blood sample (4 ml in EDTA-coated sterile tubes and 8 ml in regular tubes) will be collected after the participants fast overnight. In addition to the indexes of liver and renal function (alanine aminotransferase (ALT), AST, creatinine), blood glucose, insulin, the lipid profile (TC, TGs, high-density lipoprotein cholesterol (HDL-C) and LDL-C) and CRP will be tested on the day of blood collection. Enzymatic methods (Biosino Biotechnology Company Ltd., Beijing, China) will be used for measuring serum hepatic enzymes, including ALT and AST. Serum creatinine will be determined using the Jaffe method. Insulin concentrations ($\mu\text{U}/\text{mL}$) will be measured with a chemiluminescence microparticle immunoassay, high-sensitive CRP will be measured using the immunoturbidimetry assay, and fasting blood glucose (FBG) (mmol/L) will be measured by using the enzymatic colorimetric method with glucose oxidase using a commercially available kit. IR will be estimated by the homeostasis model assessment of insulin resistance (HOMA-IR): fasting insulin ($\mu\text{U}/\text{mL}$)*(fasting glucose (mmol/L)/22.5) [24]. The lipid profile will be determined by colorimetric methods using commercial kits (Biosino Biotechnology Company Ltd., Beijing, China) in a Hitachi 7080

automated analyser (Hitachi, Ltd., Tokyo, Japan). Serum lutein ($\mu\text{mol/L}$) will be analysed by high-performance liquid chromatography-tandem mass spectrometry. Retinol-binding protein 4 (RBP4) ($\mu\text{g/mL}$) and adiponectin ($\mu\text{g/mL}$) will be measured using an enzyme-linked immunosorbent assay (ELISA) kit (Adipogen, San Diego, CA, USA). Serum levels of MCP-1, TNF- α , IL-6, and interleukin-1 β (IL-1 β) will be measured using the flow cytometry method (FCM).

Participants will be required to provide spot urine samples on the day of the screening and at test visit 1 and test visit 3. A routine urine test will be performed on the day of collection. Faecal samples will be collected at test visit 1 and visit 3 using a stool specimen collection kit, which includes the operating instructions, an ice pack, gloves, one sterile container and spoon, a sealed plastic pouch and a cool box. Participants will collect their faecal samples and bring them to the CHSC, and then the samples will be transported and stored for further analysis.

A research biobank will be established in relation to this trial, where blood, urine and faecal samples will be stored with an identification number for later analysis of biomarkers. Participants will be informed about the research biobank before signing the informed consent form. Only investigators and the research team will retain the right to access the relevant data.

Dietary assessments

At the screening periods, eligible participants will complete a questionnaire on food intake, which captures information on how many servings of vegetables rich in lutein they consume, including sweet potato leaves, spinach, broccoli, collards, leeks, lettuce and so on. This questionnaire provides a reference to roughly evaluate dietary lutein intake. At each test visit, individuals will be required to provide three days of 24-h diet recall via the phone or the internet. The data will be collected by and calculated by a professional nutritionist according to the Chinese Food Composition Database (2009) and the United States Department of Agriculture Nutrients Database [28–29]. At each follow-up, questions on whether the participants have changed their diets will be asked, including questions regarding a significant reduction or increase in dietary intake.

Study outcomes

The primary outcome is changes in the inflammatory biomarkers between the intervention and placebo group from baseline (test visit 1) to 12 weeks later (test visit 2). The secondary objectives are to assess changes in the anthropometric indexes, including weight, WC, HC and body composition.

Data management and dissemination of results

Individuals' data or other related information will be kept in a file located in the principal investigator's office. The authorized study team will enter the information into the electronic database using double-entry methods. The private personal information (e.g., ID number and telephone) will be hidden and restricted to the principal investigator. The electronic database will be unified and managed by the Shenzhen Nanshan Center for Chronic Diseases Control. The results will be presented at scientific conferences as abstracts, oral presentations or posters. In addition, the results of the present study will be disseminated through publication in an international peer-reviewed journal.

Side effects and safety assessment

There are no side effects of 10 mg/d of lutein supplementation. An observed safe level (OSL) of 20 mg/d for lutein has been suggested [30]. There is no anticipated harm or compensation for participation in this study. All participants can contact a research assistant at any time if they feel uncomfortable. All serious and non-serious adverse events and/or reactions involving capsule supplementation will be recorded by the research assistant. The allocated treatment may be performed without blinding or may be discontinued under special circumstances during the study if the investigator deems it necessary. If possible, the patients who discontinued or deviated from the protocol will be followed up regarding all endpoints.

Statistical analysis

Two populations will be used in the analyses. The intention-to-treat (ITT) population will include all participants who have been randomized, while the per-protocol (PP) population will include all participants who accomplish the entire intervention. The baseline characteristics of the study will be summarized as the means \pm standard deviations (SDs) for parametrically distributed data, geometric mean values (and 95% confidence intervals) for nonparametrically distributed data, and numbers (percentages) for categorical data.

Differences between participants who complete and withdraw from the trial will be analysed using an independent t test or the Mann-Whitney test for continuous variables (e.g., age) and the chi-square test for categorical variables (e.g., sex). For primary and secondary outcomes, analysis of covariance will be used to examine differences between lutein supplement and placebo at 12 weeks, adjusting for potential confounding factors and effect modifiers (e.g., baseline age and sex). The present study has no plan for subgroup analysis. Our statistical analysis will be performed by using R software, and the results will be considered significant at $P \leq 0.05$.

Discussion

This study was designed to test the hypothesis that a lutein intervention will significantly modulate inflammatory factors and metabolic risk factors in people with central obesity compared with the effects

observed in a control group receiving the placebo capsules.

In designing this clinical study, several key decisions were made to overcome the current limitations in the published literature. Previous studies on the antioxidant and anti-inflammatory properties of lutein mainly focused on the early atherosclerosis population [17, 31, 32]. However, as far as we are aware, well-controlled lutein supplementation is not common, and this study will be the only study of its type to be conducted in the context of central obesity. Central obesity is a state of chronic low-grade inflammation characterized by elevated concentrations of circulating inflammatory markers, which may be a critical link between metabolic disorders such as IR and diabetes [12, 33]. Therefore, individuals with central obesity also deserve attention.

Second, when focusing on central obesity, subjects with deficient lutein intake were considered. A larger body of research has indicated that dietary lutein intake and/or serum lutein levels are negatively associated with adiposity [22–24]. In addition, a previous longitudinal study found that obese subjects had lower concentrations of total carotenoids (including lutein) than subjects with a BMI less than 22 kg/m² [34]. These results indicate that central obesity may require more antioxidants to protect against oxidative stress and inflammation generated by adipose tissue.

However, we need to confront that this clinical study has some limitations. First, the calculation of the dietary lutein intake is crude in the screening period and will be a reference for us to choose people who have a relatively lower intake. Second, this study will explore the short-term impact of the intervention because the participants will be treated for only 12 weeks. However, the development of metabolic diseases is a long and gradual process and can be influenced by other factors. Improvements in the inflammatory biomarkers and metabolic risk factors will not suggest that lutein intervention can prevent metabolic diseases; however, it can offer us a possibility for the prevention of inflammatory diseases. Whether lutein intervention can prevent metabolic diseases requires long-term intervention experiments.

Trial Status

The trial commenced recruitment in June 2019 and is currently open for recruitment. Recruitment will cease when 120 participants have been randomized. It is anticipated that this target will be reached by October 2019.

Abbreviations

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BP: blood pressure; BMI: body mass index; CHSC: Community Health Service Centre; CRP: C-reactive protein; FBG: fasting blood glucose; HC: hip circumference; HDL-C: high-density lipoprotein cholesterol; ICAM-1: intercellular cell adhesion molecule-1; IL-6: interleukin-6; IL-1 β : interleukin-1 β ; IPAQ-short form: short form of the International Physical Activity Questionnaire; IR: insulin resistance; LDL-C: low-density lipoprotein cholesterol; MCP-1: monocyte chemoattractant protein-1; MMSE: Mini-mental State Examination; PAL: physical activity level;

RBP4: retinol-binding protein 4; TC: total cholesterol; TG: triglycerides; TNF- α : tumour necrosis factor- α ; WC: waist circumference; RCT: randomized controlled trial; WHtR: waist-to-height ratio; WHR: waist-to-hip ratio.

Declarations

Ethics approval and consent to participate

Ethics approval for this study was approved by the Shenzhen Nanshan Center for Chronic Diseases Control Ethical Review Committee (project: II20170014). The trial was registered on the Chinese Clinical Trial Registry (ChiCTR) on 30 August 2018 (ChiCTR Number: 1800018098). The study will be conducted in accordance with the ethical standards of the responsible Committee on Human Experimentation (institutional and regional) and the guidelines for the design, conduction, and reporting of human intervention studies. Written informed consent will be obtained from all eligible patients before enrolment.

Consent for publication

The authors obtained consent from the participants to publish individual patient data.

Availability of data and material

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was funded by the Chinese Nutrition Society (CNS) Nutrition Research Foundation (No. CNS-DSM2018A34) and the Health and Family Commission of Shenzhen Municipality Funded Project (No. SZSJ2017001). None of the funding organizations have been involved in the design of the study or data collection, management, analysis or interpretation.

Authors' contributions

The protocol was developed by LP-H and XL-P, who is the sponsor of the study. LP-H, XL-P, JZ and DZ contributed to study conception and design and project planning. The primary investigators are JZ and DZ, who are responsible for identifying potential recruits and obtaining consent. NW and ZW-Z

contributed to laboratory assays, and CY-W provided advice on the statistical analysis. LP-H, XL-P and JZ drafted and revised the initial manuscript. All authors read and approved the final manuscript. XL-P is the contact for public queries and the delegated contact for scientific queries (e-mail address: xiaolinpeng@hotmail.com. Telephone number: +86–755–26404209. Postal address: Department of Non-communicable Disease Prevention and Control, Shenzhen Nanshan Center for Chronic Disease Control, 7 Huaming Road Shenzhen 518054, China).

Acknowledgements

Not applicable.

References

1. World Health Organization. Obesity and overweight. <https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight>. Access 20 Jun 2019.
2. Hinnouho GM, Czernichow S, Dugravot A, Nabi H, Brunner EJ, Kivimaki M, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. *European heart journal*. 2015;36(9):551–9.
3. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body Fatness and Cancer—Viewpoint of the IARC Working Group. *The New England journal of medicine*. 2016;375(8):794–8.
4. Leggio M, Lombardi M, Caldarone E, Severi P, D’Emidio S, Armeni M, et al. The relationship between obesity and hypertension: an updated comprehensive overview on vicious twins. *Hypertension research: official journal of the Japanese Society of Hypertension*. 2017;40(12):947–63.
5. Zhang C, Rexrode KM, van Dam RM, Li TY, Hu FB. Abdominal obesity and the risk of all-cause, cardiovascular, and cancer mortality: sixteen years of follow-up in US women. *Circulation*. 2008;117(13):1658–67.
6. Katzmarzyk PT, Mire E, Bouchard C. Abdominal obesity and mortality: The Pennington Center Longitudinal Study. *Nutr Diabetes*. 2012;2:e42.
7. Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G, et al. Oxidative stress in obesity: a critical component in human diseases. *International journal of molecular sciences*. 2014;16(1):378–400.
8. Liza K. Phillips JBP. The Link Between Abdominal Obesity and the Metabolic Syndrome. *Current Hypertension Reports* 2008;10:156–64.
9. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, Esquivel-Soto J, Morales-Gonzalez A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. *International journal of molecular sciences*.

2011;12(5):3117–32.

10.Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. *Nutrition, metabolism, and cardiovascular diseases: NMCD*. 2007;17(4):319–26.

11.Hocking S, Samocha-Bonet D, Milner KL, Greenfield JR, Chisholm DJ. Adiposity and insulin resistance in humans: the role of the different tissue and cellular lipid depots. *Endocr Rev*. 2013;34(4):463–500.

12.Sam S, Haffner S, Davidson MH, D'Agostino RB, Sr., Feinstein S, Kondos G, et al. Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. *Diabetes care*. 2009;32(5):932–7.

13.Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. *Circulation*. 2007;116(11):1234–41.

14.Indulekha K, Anjana RM, Surendar J, Mohan V. Association of visceral and subcutaneous fat with glucose intolerance, insulin resistance, adipocytokines and inflammatory markers in Asian Indians (CURES–113). *Clin Biochem*. 2011;44(4):281–7.

15.Huang YM, Dou HL, Huang FF, Xu XR, Zou ZY, Lin XM. Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration. *BioMed research international*. 2015;2015:564738.

16.Kijlstra A, Tian Y, Kelly ER, Berendschot TT. Lutein: more than just a filter for blue light. *Prog Retin Eye Res*. 2012;31(4):303–15.

17.Xian-Rong Xu, Zhi-Yong Zou, Xin Xiao, Yang-Mu Huang, Xun Wang, Lin X-M. Effects of lutein supplementation on serum inflammatory cytokines, ApoE and lipid profiles in early atherosclerosis population. *Journal of Atherosclerosis and Thrombosis* 2013;20:170–7.

18.Wang MX, Jiao JH, Li ZY, Liu RR, Shi Q, Ma L. Lutein supplementation reduces plasma lipid peroxidation and C-reactive protein in healthy nonsmokers. *Atherosclerosis*. 2013;227(2):380–5.

19.McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, et al. Lycopene intervention reduces inflammation and improves HDL functionality in moderately overweight middle-aged individuals. *The Journal of nutritional biochemistry*. 2013;24(1):163–8.

20.Palozza P, Parrone N, Simone RE, Catalano A. Lycopene in atherosclerosis prevention: an integrated scheme of the potential mechanisms of action from cell culture studies. *Arch Biochem Biophys*. 2010;504(1):26–33.

21.Han H, Cui W, Wang L, Xiong Y, Liu L, Sun X, et al. Lutein prevents high fat diet-induced atherosclerosis in ApoE-deficient mice by inhibiting NADPH oxidase and increasing PPAR expression. *Lipids*. 2015;50(3):261–73.

22. Ford ES, Gillespie C, Ballew C, Sowell A, Mannino DM. Serum carotenoid concentrations in US children and adolescents. *The American journal of clinical nutrition*. 2002;76(4):818–27.
23. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. *Diabetes*. 2003;52(9):2346–52.
24. Sluijs I, Beulens JW, Grobbee DE, van der Schouw YT. Dietary carotenoid intake is associated with lower prevalence of metabolic syndrome in middle-aged and elderly men. *The Journal of nutrition*. 2009;139(5):987–92.
25. Gao Q, Zhong C, Zhou X, Chen R, Xiong T, Hong M, et al. The association between intake of dietary lycopene and other carotenoids and gestational diabetes mellitus risk during mid-trimester: a cross-sectional study. *The British journal of nutrition*. 2019:1–22.
26. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med*. 2013;158(3):200–7.
27. Xu X-R, Zou Z-Y, Xiao X, Huang Y-M, Wang X, Lin X-M. Effects of Lutein Supplement on Serum Inflammatory Cytokines, ApoE and Lipid Profiles in Early Atherosclerosis Population. *Journal of Atherosclerosis and Thrombosis*. 2013;20(2):170–7.
28. Yang YX, Wang GY, Pan XC. *China Food Composition Table (2nd ed)*. Beijing: Peking University Medical Press; 2009.
29. United States Department of Agriculture and Agricultural Research Service. USDA Food Composition Database. <http://adb.nal.usda.gov/ndb/nutrients/index>. Access 11 Jun 2019.
30. Shao A, Hathcock JN. Risk assessment for the carotenoids lutein and lycopene. *Regul Toxicol Pharmacol*. 2006;45(3):289–98.
31. Zou ZY, Xu XR, Lin XM, Zhang HB, Xiao X, Ouyang L, et al. Effects of lutein and lycopene on carotid intima-media thickness in Chinese subjects with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. *The British journal of nutrition*. 2014;111(3):474–80.
32. Zou Z, Xu X, Huang Y, Xiao X, Ma L, Sun T, et al. High serum level of lutein may be protective against early atherosclerosis: the Beijing atherosclerosis study. *Atherosclerosis*. 2011;219(2):789–93.
33. Kelli HM, Corrigan FE, 3rd, Heintz RE, Dhindsa DS, Hammadah M, Samman-Tahhan A, et al. Relation of Changes in Body Fat Distribution to Oxidative Stress. *Am J Cardiol*. 2017;120(12):2289–93.
34. Andersen L, Jacobs DR, Gross MD, Schreiner PJ, Williams DO, Lee D-H. Longitudinal associations between body mass index and serum carotenoids: the CARDIA study. *British Journal of Nutrition*. 2006;95(2):358–65.

Tables

Table 1. Schedule for screening, intervention and follow-up (test visit)

	Screening (-4 week)	Test visit 1 (week 0)	Test visit 2 (week 6)	Test visit 3 (week 12)
Screening questionnaire	X			
Demographic data	X			
Medication, health status and any changes	X	X	X	X
Informed consent	X			
Height and weight	X	X	X	X
Waist circumference and hip circumference	X	X	X	X
Body composition (bioelectric impedance)	X	X	X	X
Blood pressure	X	X	X	X
Blood sample	X	X	X	X
Allocation		X		
Physical activity questionnaire		X	X	X
Mini-mental State Examination		X		X
24-h diet recall		X	X	X
Spot urine sample	X	X		X
Faecal sample		X		X
Provided supply of capsules		X	X	
Tablet count			X	X
Compliance assessment			X	X
Assess adverse reactions			X	X
Collect unused test product			X	X

Table 2. Biological and anthropometric parameters analysed in the lutein supplementation study

	Variable*	Screening	Test visit 1	Intermediate visit	Test visit 2
		(-4 week)	(week 0)	(week 6)	(week 12)
Biological	TC	X	X	X	X
	TGs	X	X	X	X
	HDL-c	X	X	X	X
	LDL-c	X	X	X	X
	ALT	X	X	X	X
	AST	X	X	X	X
	Creatinine	X	X	X	X
	FBG	X	X	X	X
	Insulin	X	X	X	X
	Lutein	X	X	X	X
	RBP4		X		X
	Adiponectin		X		X
	IL-6		X		X
	IL-1 β		X		X
	CRP		X		X
	MCP-1		X		X
TNF- α		X		X	
Anthropometric measurement	WC	X	X	X	X
	HC	X	X	X	X
	BMI	X	X	X	X
	WHR	X	X	X	X
	WHtR	X	X	X	X
	BP	X	X	X	X

* ALT: alanine aminotransferase; AST: aspartate aminotransferase; BP: blood pressure; BMI: body mass index; CRP: C-reactive protein; FBG: fasting blood glucose; HC: hip circumference; HDL-C: high-density lipoprotein cholesterol; IL-6: interleukin-6; IL-1 β : interleukin-1 β ; LDL-C: low-density lipoprotein cholesterol; MCP-1: monocyte chemoattractant protein-1; RBP4: retinol-binding protein 4; TC: total cholesterol; TGs: triglycerides; TNF- α : tumour necrosis factor- α ; WC: waist circumference; WHtR: waist-to-height ratio; WHR: waist-to-hip ratio.

Supplementary File Legend

Additional file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Figures




Figure 1. Flow chart of the trial

Figure 1

Flow chart of the trial.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile1SPIRITchecklist.doc](#)